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Sho-saiko-to is the most popular herbal medicine in
Japan. We investigated the anti-tumor and anti-metastatic
effects of Sho-saiko-to and its chemically defined ingredi-
ents on the primary skin melanoma that developed in a
metallothionein-I (MT)/ret transgenic mouse line and on
a melanoma cell line (Mel-ret), which was derived from
a primary tumor developed in a MT/ret transgenic mouse.
In vitro, Sho-saiko-to suppressed the growth of Mel-ret
cells more strongly than any single ingredient of Sho-
saiko-to, although baicalin as one of several ingredients
tested also suppressed it significantly. In vivo, Sho-saiko-
to (i) significantly (p < 0.02) prolonged the onset of
tumor development (1.5 mo), (ii) definitely retarded the
transition to malignancy, (iii) significantly decreased the
An effective protocol for the prevention and therapy ofmelanoma is urgently needed, because the recent recordreduction in the Earth’s ozone layer blocking the sun’sultraviolet rays may worsen the prediction made in 1987that one in 90 Caucasians in the U.S.A. will develop
skin melanoma by the turn of the century (Gleason et al, 1993).
Sho-saiko-to, which consists of seven crude ingredients extracted
from herbs, has been widely used for chronic hepatitis and liver
cirrhosis in Japan (Oka et al, 1995), but has yet to become popular in
Western countries. Recently, Yano et al (1994) showed that Sho-saiko-
to suppresses the proliferation of hepatocellular carcinoma cell lines
in vitro by inducing apoptosis and arrest at the G0/G1 phase; however,
there are no reports regarding whether Sho-saiko-to has an effect on
primary melanoma development, the shift to malignant stage
(melanoma) from benign stage (melanocytic nevus), and the metastasis
of primary melanoma, mainly because no earlier animal models were
suitable to test these points.
Previously, we have succeeded in establishing a transgenic mouse
line in which melanocytic tumors primarily develop, by introducing
the ret oncogene fused to the mouse metallothionein-I (MT) promoter-
enhancer (Iwamoto et al, 1991). The pathologic changes in MT/ret
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incidence of distant metastasis to brain (p < 0.002), kidney
(p < 0.05), and liver (p < 0.05) at the malignant stage,
and (iv) significantly (p < 0.02) prolonged life span
(2.6 mo). Moreover, Sho-saiko-to and baicalin down-
regulated the matrix metalloproteinase-2 and 29 expres-
sion levels, and upregulated their inhibitor expression
level in both the primary tumors and Mel-ret cells. In
conclusion, Sho-saiko-to displayed anti-tumor and anti-
metastatic effects on melanoma with regulation of the
balance of matrix metalloproteinase and tissue inhibitor
of the matrix metalloproteinase levels. Key words: baicalin/
Sho-saiko-to/matrix metalloproteinase. J Invest Dermatol 111:
640–644, 1998
transgenic mice developed stepwise as the mice aged. Recently, we
have found that the melanocytic tumor that developed in MT/ret
transgenic mice of line 304 finally progressed to melanoma accompany-
ing distant metastasis (Kato et al, 1998). In this transgenic mouse line,
tumors developed mainly in the skin, where we could inspect them
throughout life. For these reasons, this transgenic mouse line appeared
especially suitable for a long-term stage-oriented examination of both
the anti-tumor and the anti-metastatic effects of drugs.
In this study, we demonstrate for the first time that Sho-saiko-to
suppresses primary tumor development, transition from the benign to
the malignant stage, and tumor growth and distant metastasis, resulting
in a prolongation of life span, in the transgenic mouse model in
which melanoma spontaneously develops. Furthermore, concerning its
mechanism of anti-tumor and anti-metastatic effects, evidence is
provided that Sho-saiko-to controls the cell cycle and expression levels
of matrix metalloproteinase (MMP) and the tissue inhibitor of matrix
metalloproteinase (TIMP) of tumor cells.
MATERIALS AND METHODS
Sho-saiko-to treatment in MT/ret transgenic mice The MT/ret trans-
genic mice had no tumors for 4.8 mo on average after birth (tumor-free stage).
Next, benign melanocytic tumors in the skin developed without exception
and grew slowly, while the tumor was histologically benign (benign stage;
corresponding with Fig 3C, D). Then, tumors that developed in the skin of
these mice suddenly began to grow rapidly with ulcers on the surface, and
displayed the histologic appearance of typical melanoma (malignant stage;
corresponding with Fig 3A, B) (Iwamoto et al, 1991; Kato et al, 1998). MT/
ret transgenic mice were randomly divided into two groups. One group
(experimental, n 5 94) was given drinking water containing 3–5 mg Sho-
saiko-to (TUMURA, Tokyo, Japan) per d per mouse, which is the usual
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human dose in conversion per weight, from 1 mo of age until death. The
other group (control, n 5 90) was given plain drinking water only. Each of
the two groups consisted of several evenly divided litters. For analysis of tumor
volume and life span, 50 transgenic mice in each group were used. For
examination of distant metastasis and/or MMP and TIMP expression levels in
primary tumors, 30 (control) or 34 (experimental) transgenic mice were tested.
Analysis of metastasis of primary tumors in MT/ret transgenic
mice Metastasis of primary tumor in 9–15 mo old litter mice of experimental
and control groups was analyzed on hematoxylin and eosin stained sequential
specimens of primary tumors, brain, kidney, liver, spleen, lung, and lymph nodes.
Cell line and culture Mel-ret cells, which had been established from the
tumor of a MT/ret transgenic mouse of line 304 as a melanoma cell line
(Taniguchi et al, 1992), were suspended in an RPMI-1640 medium supple-
mented with 10% fetal calf serum and 100 U penicillin per ml, 100 µg
streptomycin per ml, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol
(complete medium) in 60 3 15 mm tissue culture dishes (Coming, NY). The
water soluble reagent, Sho-saiko-to, was dissolved in the complete medium to
a concentration of 10 mg per ml. This solution was centrifuged (1200 3 g,
20 min) to remove insoluble ingredients, and the supernatant was sequentially
passed through 0.22 µm filters for sterilization. The known representative
chemical ingredients of Sho-saiko-to, such as baicalin, glycyrrhizin, baicalein,
saikosaponin-d, and ginsenoside Rb1, were obtained from Wako Pure Chemical
Industries (Osaka, Japan). Each of these ingredients of Sho-saiko-to was first
dissolved in dimethylsulfoxide (Wako Pure Chemical Industries), and diluted
in complete medium to 0.05% or lower concentration as described elsewhere
(Yano et al, 1994) because it was not water soluble. Corresponding to the
earlier report of Yano et al (1994) that ø2000 µg Sho-saiko-to per ml had no
influence on the viability of normal human peripheral lymphocytes and normal
rat hepatocytes within 3 d of culture, Sho-saiko-to at the concentration of
400 µg per ml and the amount of each ingredient (baicalin, baicalein,
glycyrrhizin, saikosaponin-d, and ginsenoside Rb1) contained in 400 µg Sho-
saiko-to per ml displayed no nonspecific cytotoxicity on normal mouse splenic
lymphocytes in vitro, either when cell viability was examined after 24 h
incubation by the dye exclusion test or when growth response to mitogen
(concanavalin A) was measured by [3H]thymidine uptake. In human, after
oral treatment of clinically applicable amounts of Sho-saiko-to, the blood
concentration of baicalein roughly reached the level of baicalein contained in
200 µg Sho-saiko-to per ml (Nishioka et al, 1992). Therefore, 400 µg Sho-
saiko-to per ml is not too high a concentration for practical use. DNA synthesis
of Mel-ret cells in the presence or absence of Sho-saiko-to or its ingredients
was measured by [3H]thymidine uptake as described previously (Kato et al, 1994).
Analysis of cell cycle Tumor cells prepared from the Sho-saiko-to treated
and untreated MT/ret transgenic mice were analyzed for cell cycle by laser
flow-cytometry using propidium iodide as a dye staining DNA, according to
the previously described method (Hayakawa et al, 1994).
Analysis of MMP-2, MMP-9, and TIMP-2 expression The immuno-
blotting assay of MMP-2, MMP-9, and TIMP-2 proteins was done by the
method described earlier (Pu et al, 1996). Fixed amounts (50 µg per lane) of
total cell lysates prepared from tumors developed in MT/ret transgenic mice or
Mel-ret-cells were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes (Nihon
Millipore Kogyo KK, Yonezawa, Japan). The membranes were incubated
overnight with the anti-MMP-2 polyclonal antibody, which was prepared by
immunizing rabbits with purified MMP-2 from murine colon carcinoma cells,
anti-MMP-9 monoclonal antibody (9AG) (Sakata et al, 1996), or anti-TIMP-2
polyclonal antibody (Chemicon International, CA), followed by incubation
with the second antibody (goat anti-rabbit or rat IgG conjugated to horseradish
peroxidase; Tago, Burlingame, CA) for 1.2 h. The proteins were visualized by
western blot chemiluminescence reagent (DuPont NEN, Boston, MA) as
directed by the manufacturer.
Statistical analysis Analysis of tumor volume and life span in the Sho-saiko-
to treated and control mice was done by the Mann–Whitney U test. Analysis
of the percentage of metastasis in the Sho-saiko-to treated and untreated control
mice was done by chi-square (χ2) test or Fisher’s exact test.
RESULTS
Sho-saiko-to inhibits growth of primary melanocytic tumors
in MT/ret transgenic mice As shown in Fig 1, we first examined
the effect of Sho-saiko-to and its ingredients on the growth of Mel-
ret cells in vitro. Sho-saiko-to (p , 0.005) and one of its main
ingredients, baicalin (p , 0.02), significantly inhibited DNA synthesis
Figure 1. Sho-saiko-to inhibits the growth of melanoma cells in vitro.
Sho-saiko-to (400 µg per ml) or each of its main ingredients was added on day
1 of in vitro culture of Mel-ret cells. Their DNA synthesis on day 3 was
measured by [3H]thymidine uptake assay. Each column shows the mean 6 SD
of six cultures. Shown is a representative of four experiments. *,†Significantly
different (*p , 0.005; †p , 0.02) from the control by the Mann–Whitney U test.
Figure 2. Sho-saiko-to inhibits primary development and growth
of melanocytic tumors in MT/ret transgenic mice. Tumor volumes
(mean 6 SD) are shown for Sho-saiko-to treated (d, n 5 50) and untreated
control (s, n 5 50) transgenic mice on the log (A) and linear (B) scales.
*,†,§,¶Significantly different (*p , 0.001; †p , 0.005; §p , 0.01; ¶ p , 0.05)
from the untreated control by the Mann–Whitney U test. Tumor volumes in
mice that died before 18 mo were calculated as a continuation of the volume
up to 18 mo.
of Mel-ret cells, compared with control; and the level of DNA synthesis
of Mel-ret cells treated with Sho-saiko-to was significantly lower
(p , 0.005) than that of cells treated with any single ingredient
including baicalin. Following this basic observation, which corresponds
to the earlier result of Yano et al (1994) for human cancer cells, we
examined the effect of Sho-saiko-to on the growth of primary tumors
in MT/ret transgenic mice. As shown in Fig 2, Sho-saiko-to displayed
anti-tumor effects at different stages of tumor growth. First, the duration
of the tumor-free stage in Sho-saiko-to treated transgenic mice
(6.3 6 2.6 mo, n 5 50) was significantly longer (p , 0.02) than that
of untreated mice (4.8 6 2.6 mo, n 5 50). Second, Sho-saiko-to
remarkably lowered the rate of growth of tumors after their initial
development. Whereas primary tumors quickly shifted from ,150 mm3
(3.3 mo after birth on average) to .5000 mm3 (7.5 mo after birth on
average) in Sho-saiko-to untreated control mice, those rates remained
at ,150 mm3 (9.0 mo after birth on average) for a long time in Sho-
saiko-to treated mice. Histologic examination of some tumors from
Sho-saiko-to treated or untreated control mice confirmed that tumors
with a volume of ,150 mm3 are at the benign stage, whereas those
with a volume of .5000 mm3 are at the malignant stage. In the
photographs of representative Sho-saiko-to treated and untreated
control 10 mo old transgenic mice of the same litter, a tumor in a
treated mouse was kept at the benign stage (Fig 3C, D), whereas that
in an untreated mouse reached the malignant stage (Fig 3A, B). These
results suggest that Sho-saiko-to delays both the onset of primary
tumor development and the shift from benign stage to malignant stage
of the tumor. During the malignant stage, Sho-saiko-to still inhibited
tumor growth significantly, though less markedly than during the
benign stage.
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Figure 3. Representative 10 mo old MT/ret transgenic mice of the same
litter treated or untreated with Sho-saiko-to. Macroscopic (A, C) and
microscopic (B, D; hematoxylin and eosin staining) appearance of the control
(A, B) and experimental (C, D) transgenic mice were displayed. They all exhibit
black coat color (A, C). Note the severe systemic skin melanosis and black
tumors (A, 40 3 35 3 30 mm; C, 6 3 6 3 3 mm; indicated by arrows).
Tumors frequently developed in back skin as shown in this picture, but they
also developed in other areas of skin. In the control mouse, the tumor consisted
of atypical cells bearing variable sizes of nuclei with high mitotic activity
(malignant feature) (B; hematoxylin and eosin staining). In the experimental
mouse (D), the tumor consisted of round cells bearing round nuclei without
mitotic activity (benign feature). Scale bar: 15 µm.
Table I. Sho-saiko-to partially inhibits metastasis of primary
melanocytic tumors at the malignant stagea
Incidence of metastasis






Lymph node 53.3% 52.9%
aSho-saiko-to treated (n 5 34) and untreated (n 5 30) MT/ret transgenic mice that
bear tumors at the malignant stage were sacrificed for examination of metastasis of tumors.
*,†Significantly different values (*p , 0.002; †p , 0.05) from those for the control group
by chi-square test (brain, lung, and lymph node) or Fisher’s exact test (kidney, liver,
and spleen).
Sho-saiko-to inhibits metastasis of primary melanocytic tumors
at the malignant stage We next examined the effect of Sho-saiko-
to on distant metastasis in MT/ret transgenic mice. The incidences (%)
of distant metastasis for brain (p , 0.002), kidney (p , 0.05), and
liver (p , 0.05) in the transgenic mice given Sho-saiko-to (n 5 34)
were significantly lower than those in the controls (n 5 30), when
mice bearing malignant stage tumors of equivalent volumes (Table I)
and those from littermate mice (data not shown) were examined.
There was little or no difference, however, between the experimental
and control groups in the incidence of distant metastasis for spleen,
lung, and lymph node. These results suggest that Sho-saiko-to partially
inhibits the distant metastasis of melanoma at the malignant stage.
Sho-saiko-to prolongs the life span of MT/ret transgenic
mice We further studied the effect of Sho-saiko-to on the life span
of MT/ret transgenic mice. Figure 4 shows the survival time and rate
of Sho-saiko-to treated (n 5 50) and untreated (n 5 50) MT/ret
transgenic mice. Mean life span of the former (12.6 6 5.0 mo) was
significantly (p , 0.02) longer than that of the latter (10.0 6 4.3 mo).
Figure 4. Sho-saiko-to prolongs the life span of MT/ret transgenic
mice. Survival rates of Sho-saiko-to treated (j; n 5 50) and untreated
control ( ; n 5 50) transgenic mice. *Significantly different (p , 0.02)
from the untreated control by the Mann–Whitney U test.
Figure 5. Sho-saiko-to regulates the MMP-2, MMP-9, and TIMP-2
expression levels in primary melanocytic tumors in MT/ret transgenic
mice. (A) The MMP-2 and MMP-9 protein expression levels are shown in
the primary tumors with different volumes (lane 1, 100 mm3; lane 2, 112 mm3;
lane 3, 2250 mm3; lane 4, 2704 mm3; lane 5, 13,750 mm3; lane 6, 13,750 mm3;
lane 7, 26,250 mm3; lane 8, 32,000 mm3; lane 9, 102,250 mm3; lane 10,
120,000 mm3) developed in Sho-saiko-to treated (1) (lanes 2, 4, 6, 8, and 10)
and untreated control (–) (lanes 1, 3, 5, 7, and 9) MT/ret transgenic mice. The
tumors for lanes 2 and 9, and those for lanes 4 and 7 were taken from the same
litter MT/ret transgenic mice. (B) The TIMP-2 protein expression levels are
shown in the primary tumors with different volumes (lane 1, 97 mm3; lane 2,
120 mm3; lane 3, 2450 mm3; lane 4, 2670 mm3; lane 5, 20,000 mm3; lane 6,
20,000 mm3) developed in Sho-saiko-to treated (1) (lanes 2, 4, and 6) and
untreated control (–) (lanes 1, 3, and 5) mice. Similar results were also obtained
with tumors from other control (n 5 15) and experimental (n 5 15) mice.
Survival rate of the former was also significantly (p , 0.02) higher
than that of the latter from 12 mo after birth.
Sho-saiko-to arrests cell cycle of primary melanocytic tumors
at the G0/G1 phase The percentage of the G0/G1 phase of the
tumor cells (mean 6 SD) from the experimental mice (G0/G1,
86.7 6 1.4%; S, 3.0 6 1.1%; G2/M, 10.3 6 0.7%, n 5 4) was
significantly higher (p , 0.01) than that from the control mice (G0/
G1, 75.9 6 3.1%; S, 6.9 6 2.7%; G2/M, 17.2 6 2.6%, n 5 4) when
we examined the histologically determined benign stage tumors of
equivalent volumes. These results suggest that Sho-saiko-to suppresses
the tumor growth through cell cycle arrest at the G0/G1 phase in vivo.
Sho-saiko-to changes the levels of MMP and TIMP-2 in melano-
cytic tumors In order to partially determine the mechanism of the
anti-tumor and anti-metastatic effects of Sho-saiko-to, we compared
the levels of MMP and TIMP-2 expression in tumors from the Sho-
saiko-to treated and untreated mice. In tumors of control MT/ret
transgenic mice, the protein expression levels of MMP-9 and MMP-2
remarkably increased when tumor size reached .20,000 mm3 (fully
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Figure 6. Sho-saiko-to and balcalin
regulate the MMP-2, MMP-9, and TIMP-2
expression levels in melanoma cells in vitro.
Mel-ret cells were cultured for 3 d in the
absence (lane 1) or presence of 400 µg Sho-
saiko-to per ml (lane 2) or baicalin contained
in 400 µg Sho-saiko-to per ml (lane 3) for
measurement of MMP-9 (A), MMP-2 (B), and
TIMP-2 (C) protein expression levels. Upper
panels show representative pictures from four
experiments, and the result of statistical analysis
of data (n 5 4) measured by densitometry for
the bands are shown in the lower panels. Each
column shows the mean 6 SD. *Significantly
different (p , 0.05) from the control (u) by
the Mann–Whitney U test.
malignant stage) (lanes 7 and 9 in Fig 5A). No such increase was seen
in tumors from age-matched Sho-saiko-to treated MT/ret transgenic
mice (lane 2 versus lane 9 as control; lane 4 versus lane 7 as control in
Fig 5A). Furthermore, the increase in the MMP-2 and MMP-9
expression levels in tumors from Sho-saiko-to treated mice was not so
remarkable as that in tumors from untreated control mice, even when
compared with size-matched tumors from mice of different ages (lane
8 versus lane 7 as control; lane 10 versus lane 9 as control in Fig 5A).
In contrast, as compared with the levels in size-matched tumors from
the untreated control mice, the levels of TIMP-2 expression markedly
increased in both small (lane 2 versus lane 1 as control; lane 4 versus lane
3 as control) and large (lane 6 versus lane 5 as control) stages of tumors
from the Sho-saiko-to treated mice (Fig 5B).
Finally, we examined whether the regulation of MMP and TIMP
levels by Sho-saiko-to in vivo would hold for Mel-ret cells in vitro, and
whether baicalin plays a crucial role in this regulation. There was little
difference in the levels of MMP-2, MMP-9, and TIMP-2 expression
between Sho-saiko-to or baicalin treated cells and untreated control
cells on days 1 and 2 of culture (data not shown). As shown in Fig 6,
however, both Sho-saiko-to and baicalin downregulated the expression
of MMP-2 and MMP-9, and upregulated the expression of TIMP-2
on day 3 of culture.
DISCUSSION
We have demonstrated that Sho-saiko-to delays both the onset of
primary tumor (melanoma) development and the shift from benign
stage to malignant stage, which results in more than 25% prolongation
of the life span of tumors developing transgenic mice. The anti-tumor
and anti-metastatic effects of this herbal medicine partially protected
animals from primarily developing tumors. Any earlier reports did not
examine the long-term effects of the medicine on individual animals
ranging from the early life before tumor development to the end stage
of tumor death. In this study, we have provided evidence that Sho-
saiko-to inhibits proliferation of tumor cells through cell cycle arrest
at the G0/G1 phase in vivo. One of the mechanisms of the anti-tumor
effects of this medicine against melanoma development in transgenic
mice should therefore be the regulation of cell cycle, as suggested
previously by an in vitro experiment with carcinoma cells (Yano
et al, 1994).
Sho-saiko-to has been further shown to partially inhibit metastasis
to distant tissues at the malignant stage. Correspondingly, the levels of
MMP-9 and MMP-2 in tumors at the malignant stage from the Sho-
saiko-to treated mice were lower than those in tumors with equivalent
volumes from untreated control mice. In contrast, the tumors from
the Sho-saiko-to treated mice had higher levels of TIMP-2 as an
inhibitor of MMP than those with an equivalent volume from control
mice. MMP are thought to be associated with remodeling in many
normal and pathologic processes, and in particular to be critical for
metastasis (Crawford and Matrisian, 1994; Himelstein et al, 1994).
Recent studies of human tissues or tumor-derived cell lines have also
suggested the importance of dysregulation of the balance of MMP and
TIMP in tumor progression including metastasis (Himelstein et al,
1994; Montgomery et al, 1994). Sho-saiko-to could therefore inhibit
metastasis of melanoma in MT/ret transgenic mice through regulating
the balance of MMP and TIMP levels.
TIMP may also regulate cell growth in a manner that is independent
of their ability to inhibit MMP activity (Bertaux et al, 1991; Hayakawa
et al, 1992; Stetler-Stevenson et al, 1992; Nemeth and Goolsby, 1993).
By transfection of complementary DNA-encoding human TIMP-2,
the growth of a human melanoma cell line (M24net cells) was markedly
reduced in the skin of immunodeficient mice (Montgomery et al,
1994). Our result that the level of TIMP-2 was upregulated in small
and medium-size tumors that developed in MT/ret transgenic mice
and Mel-ret cells by treatment with Sho-saiko-to, thereby suggests
that this upregulation may underlie the mechanism of tumor growth
inhibition and cell cycle arrest by Sho-saiko-to.
A question arises whether the demonstrated anti-tumor and anti-
metastatic effect is through regulation of the expression of the ret
oncogene. Our preliminary study, however, showed that Sho-saiko-
to treatment did not attenuate the expression of the ret oncogene in
tumors from MT/ret transgenic mice and Mel-ret cells (Kato et al,
unpublished observation). This may suggest that Sho-saiko-to affects
regulatory elements of tumor progression other than the oncogene (ret)
expression.
It is known that Sho-saiko-to consists of baicalin, baicalein, glycyrrhi-
zin, saikosaponin, and ginsenoside as chemically defined ingredients
(Zhang et al, 1993, 1995; Kato et al, 1994, 1995; Yano et al, 1994).
Our study demonstrated that, among these Sho-saiko-to ingredients,
baicalin was most potent in inhibiting the growth of Mel-ret cells, and
in changing the levels of MMP-2, MMP-9, and TIMP-2 expression
in the cells. Baicalin must therefore be one of the major ingredients
of Sho-saiko-to that is active for the anti-tumor effect regulating the
balance of MMP and TIMP levels; however, this one ingredient
probably accounts for only a portion of the herb’s entire effect on
various anti-tumor parameters in vivo. Potentially cooperative roles of
other ingredients in the overall anti-tumor effect of Sho-saiko-to in vivo
remain to be elucidated.
In short, we showed that Sho-saiko-to displays anti-tumor and anti-
metastatic effects on melanoma at least in part through the regulation
of MMP and TIMP levels in tumor cells, and that baicalin could be
one of the major ingredients of Sho-saiko-to responsible for these
effects. Because the known clinical side-effects of long-term usage of
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Sho-saiko-to are limited compared with those of other anti-turnor
drugs (Ito et al, 1982; Sameshima et al, 1987), this herbal medicine
might be useful for suppressing the overall process of the progression
of melanoma in human.
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